Recommended

Novo Nordisk bids $6.5bn for Metsera Therapeutics
MHRA to streamline UK rare disease drug regulatory pathway
Lilly invests €2.6bn in Netherlands manufacturing facility
MHRA recruits first Chief Medical and Scientific Officer
Galapagos to exit cell therapy business
Chiesi expands French metered dose inhaler facility
CPHI Milan to add AI zone for 2026
Hovione invests $100m in US spray drying manufacturing
news

Bristol Myers Squibb names new Head of Development

0
SHARES

The new appointee has over twenty years of experience in biopharma and extensive senior expertise in oncology.

Bristol Myers Squibb Dr Cristian Massacesi

Credit: PixelBiss / Shutterstock.com

Bristol Myers Squibb has appointed Dr Cristian Massacesi as its new Executive Vice President, Chief Medical Officer, and Head of Development.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Dr Massacesi will oversee both early-stage and late-stage product development from 1 August 2025, based in Princeton, New Jersey, US.

He will overtake Dr Samit Hirawat, who has been in the role for the past six years. To ensure a smooth transition, Dr Hirawat will move on from his current role on August 1, 2025. He will however, remain as an advisor at Bristol Myers Squibb until 1 November.

Dr Cristian Massacesi’s career highlights

Dr Massacesi has over two decades experience in the global biopharmaceutical field and begun his career as a medical oncologist.

“He has a proven track record of advancing breakthrough science from early through late-stage development and global regulatory approvals,” Bristol Myers Squibb explained.

Dr Massacesi’s deep scientific expertise, strong focus on clinical execution and proven track record of regulatory approvals will be instrumental as we continue to advance our pipeline…”

In his most recent roles as AstraZeneca and Alexion, Dr Massacesi served as Chief Medical Officer, and as Oncology Chief Development Officer at AstraZeneca. During his tenure, the company advanced over 150 clinical studies and achieved multiple regulatory approvals.

Dr Massacesi has also worked in senior R&D positions at Pfizer and Novartis. Here, he oversaw advancement of therapeutic development programmes for solid tumours and hematologic malignancies.

“[His] deep scientific expertise, strong focus on clinical execution and proven track record of regulatory approvals will be instrumental as we continue to advance our pipeline and deliver breakthrough medicines to even more patients around the world,” explained Christopher Boerner, PhD, Board Chair and Chief Executive Officer, Bristol Myers Squibb.

Commenting on his new tenure as EVP, Chief Medical Officer, and Head of Development, Dr Massacesi shared: “I am on a mission to discover new medicines – unlocking innovative approaches to researching and treating challenging diseases so that one day, no patient will hear that all options have been exhausted”.

Share via
Share via